How Does Endometriosis Affect Fertility? Understanding the Science

Being told you have endometriosis can instantly raise a scary question: “Does this mean I can’t get pregnant?” For many people, the uncertainty is harder than the diagnosis itself—especially because you may hear totally different stories from friends, social media, and even different clinicians.

The truth is more nuanced (and often more hopeful): endometriosis can affect fertility, but it doesn’t do so in just one way, and it doesn’t affect everyone the same way. Across multiple recent reviews and IVF studies, researchers consistently describe endometriosis-associated infertility as multifactorial—meaning it can involve pelvic anatomy, inflammation, ovarian reserve and egg yield, and sometimes the uterine environment and implantation.

This post pulls together findings from several studies to explain how endometriosis may interfere with conception, why fertility outcomes vary so widely, and what parts of this science can actually help you plan next steps.

The big picture: endometriosis affects fertility through multiple pathways

A helpful way to think about endometriosis and fertility is to imagine conception as a “chain” with several links: ovulation and egg development, pickup by the tube, fertilization, embryo development, implantation, and early pregnancy. Endometriosis can potentially tug on several links at once, and which link matters most differs person to person.

Researchers commonly group the mechanisms into four overlapping themes:

1. Mechanical/anatomical factors (adhesions, distorted tubo-ovarian anatomy)
2. Inflammation and immune signaling in the pelvis and reproductive tract
3. Ovarian reserve and egg/embryo numbers (especially with endometriomas or surgery)
4. Implantation environment (endometrial receptivity and—often overlooked—adenomyosis)

Let’s walk through each in plain language.

1) Can endometriosis block pregnancy mechanically (adhesions and anatomy)?

Yes—sometimes. Endometriosis can cause adhesions (scar-like bands) that pull organs out of their normal position. When that happens, the ovary and tube may not “meet” well, the tube may not pick up the egg efficiently, or the tube may become partially blocked. Deep disease can also interfere with pelvic function and may be associated with more severe anatomic distortion.

But an important—and validating—point from pathophysiology research is that symptoms and fertility impact don’t perfectly match what’s seen surgically. Some people have severe pain with minimal visible disease, and some have extensive disease with less pain. That mismatch happens because pain can become amplified by nerve changes and central sensitization over time, while fertility impact may depend more on whether key structures (tubes/ovaries) are affected.

Practical meaning: anatomy matters, but it’s not the whole story—and you can’t reliably predict fertility solely from pain severity.

2) How does inflammation and immune dysfunction interfere with conception?

Many modern papers emphasize that endometriosis isn’t only “misplaced tissue”—it’s also an inflammatory, immune-active condition. Studies describe peritoneal (pelvic) fluid in endometriosis as rich in inflammatory signals, oxidative stress, and immune-cell changes that may interfere with reproduction even when the tubes look open.

Across reviews, several recurring biological patterns show up:

• Local estrogen dominance and progesterone resistance within lesions and surrounding tissues. This can promote lesion persistence and may also affect the endometrium’s ability to behave “normally” across the cycle. Importantly, circulating estrogen in the blood may look normal—this is often described as a local tissue environment issue rather than a simple blood-hormone problem.
• Immune shifts such as altered macrophage activity and reduced NK-cell cytotoxicity, along with cytokine-rich inflammation. These changes can affect processes involved in fertilization, embryo development, and implantation.
• Oxidative stress and iron overload, particularly discussed in the context of endometriomas and “ferroptosis”-related pathways. Researchers describe markers of lipid peroxidation and reduced antioxidant defenses in ovarian support cells (like granulosa cells), which may impair follicle development.

What this means for patients: even if imaging suggests your anatomy is “fine,” inflammation and oxidative stress may still reduce the efficiency of conception—helping explain why some people struggle despite open tubes.

3) Does endometriosis affect egg quality—or mostly the number of eggs?

This is one of the most common worries, and the research gives a nuanced answer.

In IVF studies, a consistent pattern: fewer eggs retrieved

A large meta-analysis of ART outcomes found that, on average, people with endometriosis had fewer total oocytes retrieved and fewer mature (MII) oocytes than those without endometriosis (roughly about two fewer eggs in pooled estimates). Another IVF study similarly reported lower baseline ovarian reserve markers (AMH/AFC) and fewer oocytes and embryos despite higher medication doses.

That consistency across different datasets supports a real “signal”: endometriosis—especially when ovaries are involved—often affects ovarian reserve and ovarian response, which translates into fewer eggs and fewer embryos.

Embryo “quality” is less clear—and may be less affected than you fear

Here’s the more reassuring part: in one IVF study, when researchers adjusted for other factors, endometriosis was not associated with a worse proportion of top-quality embryos using day-2 morphology scoring. The authors argued that lower cumulative live birth rates were driven mainly by having fewer embryos available overall, meaning fewer frozen transfers to try.

Other reviews echo that the impact of endometriosis on intrinsic egg/embryo quality is debated and heterogeneous—some people seem unaffected, while others may be more sensitive to inflammatory/oxidative environments. Mechanistic papers propose plausible ways egg competence could be impaired (mitochondrial function, granulosa/cumulus cell disruption, epigenetic changes), but they also stress that clinical outcomes do not always show a consistent “egg quality” collapse.

What to take from this: endometriosis often affects quantity (response/embryo numbers) more consistently than it affects visible embryo quality—but individual experiences vary.

Endometriomas: the ovary-specific factor that often matters most

Ovarian endometriomas are repeatedly linked with lower ovarian reserve markers (like AMH and AFC) and fewer eggs retrieved in IVF. Researchers propose that nearby ovarian tissue may be harmed by inflammation, oxidative stress, and iron-rich cyst contents.

This doesn’t mean pregnancy is impossible with endometriomas. In fact, a clinical framing found in reviews is that even with reduced ovarian response, live birth rates can be comparable in some cohorts, reminding us that “fewer eggs” is not the same as “no chance.” It simply changes planning—sometimes toward earlier action, embryo banking, or minimizing unnecessary ovarian damage.

4) What about implantation? (And why adenomyosis matters)

Another source of confusion is implantation: if fertilization happens, will the embryo implant and lead to a healthy pregnancy?

Researchers describe possible implantation issues through:

• Altered endometrial receptivity markers and progesterone resistance
• Inflammatory and immune factors in the uterine environment

And there’s a major “co-factor” that comes up repeatedly: adenomyosis. Recent reviews highlight that adenomyosis often coexists with endometriosis and that meta-analyses have linked adenomyosis to lower ART pregnancy rates and higher miscarriage risk. In real life, this means that two people with similar endometriosis may have different outcomes depending on whether adenomyosis is also present—and whether it’s recognized on imaging.

Practical meaning: if you’re building a fertility plan, it’s worth asking whether your ultrasound or MRI has been reviewed specifically for adenomyosis, because it can change counseling and strategy.

Does stage (severity) predict fertility? Sometimes, but not perfectly

Patients often want a single number: “What stage am I, and what does that mean for pregnancy?”

Staging systems (like rASRM/ASRM or Enzian) are useful for describing disease consistently, but recent clinical reviews emphasize they do not reliably predict fertility outcomes. Fertility depends on which mechanisms are most active for you (tubes/anatomy, ovarian involvement, uterine factors, inflammation), plus age and baseline ovarian reserve.

One tool that is specifically discussed for prognosis after surgery is the Endometriosis Fertility Index (EFI), designed to estimate chances of spontaneous conception post-operatively. The key point is not that the EFI is perfect, but that fertility prognosis needs fertility-specific tools, not just “endo stage.”

If hormones help pain, why don’t they “fix fertility”?

A tough paradox: hormonal suppression (pill, progestins, GnRH agents, many IUD approaches) can be excellent for pain control, yet it’s generally not recommended as a way to improve natural fertility when you’re actively trying to conceive. That’s partly practical—many suppress ovulation—and partly evidence-based: recent guidance summarized in reviews repeatedly notes that hormonal suppression is not recommended solely to improve natural conception rates or to enhance future pregnancy rates after surgery.

This matters emotionally because it can feel like you must choose between symptom control and fertility goals. In reality, many people cycle between phases—symptom management when not trying, then a planned “off hormones” window with a defined next step (timed intercourse, IUI, IVF, or surgery depending on your situation).

So…will surgery improve fertility?

The evidence suggests: sometimes, for the right person at the right time.

Reviews summarizing randomized trials indicate that in minimal/mild endometriosis, laparoscopic treatment probably increases viable intrauterine pregnancy rates compared with diagnostic laparoscopy alone (moderate-quality evidence). That fits the “remove inflammatory/ectopic tissue + restore normal pelvic environment” hypothesis when anatomy isn’t severely distorted.

But surgery is not automatically a fertility win—especially when ovaries are involved:

• Endometrioma excision can reduce ovarian reserve, and some reviews describe AMH decline that can persist for months.
• In ART-focused data, prior surgery was not associated with improved clinical pregnancy rates and was associated with lower live birth in pooled analyses (an association, not proof that surgery caused the difference—people who undergo surgery may differ in important ways).

The combined message is that surgery decisions should be goal-driven (pain vs fertility), phenotype-driven (endometrioma vs superficial disease vs deep disease), and timeline-driven (age/ovarian reserve/urgency).

Timeline expectations: why outcomes can look “mixed”

One reason the research can sound contradictory is that different studies measure different endpoints:

• Per-cycle outcomes (one IVF transfer) may look similar
• But cumulative live birth (across fresh + frozen transfers) may be lower if fewer embryos are created and frozen

That distinction matters for planning. If endometriosis mainly reduces egg/embryo numbers, you might still do well per transfer—yet need more retrievals or more strategic embryo banking to reach the same cumulative chance of a live birth.

Practical takeaways (and questions to ask your doctor)

• “What do you think is my main fertility bottleneck?” (tubal/anatomy, ovarian reserve/endometrioma, implantation/adenomyosis, inflammation, male factor, age-related factors)
• “Has my imaging been reviewed for adenomyosis?” If yes, how does that change the plan?
• “What are my ovarian reserve markers (AMH, AFC) and what do they imply for timing?”
• “If we’re considering surgery, what is the goal—and what’s the ovarian reserve risk?” Ask specifically about endometrioma approach and how reserve will be protected.
• “If we do IVF, should we plan for embryo banking?” (especially if reserve is borderline or prior response suggests fewer embryos)

What we still don’t know (and why individual results vary)

Even with better science, big uncertainties remain:

• Egg “quality” effects are hard to prove in humans because we can’t directly measure true egg competence; studies often rely on embryo morphology or indirect markers, which may miss subtler effects.
• Endometriosis is not one disease. Different phenotypes (superficial, endometrioma, deep disease) and coexisting conditions (especially adenomyosis) likely drive different fertility outcomes.
• Many proposed add-ons—antioxidants, immune-modulating strategies, microbiome interventions, ferroptosis/iron-targeted therapies—are intriguing in early research, but reviews repeatedly emphasize that robust clinical validation is still needed before they can be considered proven fertility treatments.
• Observational findings about surgery and IVF outcomes can be affected by who gets selected for surgery (more severe disease, more symptoms), making cause-and-effect hard to pin down.

The most patient-relevant conclusion from the combined evidence is this: endometriosis can reduce fertility through several pathways, but identifying your dominant pathway is what turns fear into a plan.

In the next posts in this series, we’ll build on this science to talk more concretely about how people choose between surgery, IUI/IVF, and timing—and how adenomyosis changes pregnancy planning.